We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.39M
AUM Growth
-$132K
Cap. Flow
+$358M
Cap. Flow %
6,649.45%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$44.9M
3
ABBV icon
AbbVie
ABBV
+$28.7M
4
VTYX
Ventyx Biosciences
VTYX
+$23.6M
5
PCVX icon
Vaxcyte
PCVX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
26
Evolent Health
EVH
$396M
$71.7K 1.33%
1,994,717
+216,717
+12% +$7.63M
PRLD icon
27
Prelude Therapeutics
PRLD
$362M
$66.4K 1.23%
10,039,691
– –
NTRA icon
28
Natera
NTRA
$36.4B
$66K 1.22%
1,505,153
-156,200
-9% -$7.44M
KROS icon
29
Keros Therapeutics
KROS
$198M
$63.2K 1.17%
1,679,417
– –
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.88B
$62.8K 1.17%
3,196,876
– –
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$60.9K 1.13%
360,457
– –
BIIB icon
32
Biogen
BIIB
$31.8B
$60K 1.11%
224,600
+113,000
+101% +$24M
SIBN icon
33
SI-BONE Inc
SIBN
$804M
$58.8K 1.09%
3,368,000
– –
VRNA
34
DELISTED
Verona Pharma
VRNA
$58.2K 1.08%
5,694,841
– –
ARQT icon
35
Arcutis Biotherapeutics
ARQT
$3.51B
$53.5K 0.99%
2,800,000
-1,981,646
-41% -$44.9M
GH icon
36
Guardant Health
GH
$19.1B
$53.4K 0.99%
992,400
-41,000
-4% -$2.1M
XTNT icon
37
Xtant Medical Holdings
XTNT
$59.1M
$52.6K 0.98%
73,114,592
+170,674
+0.2% +$93.5K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$38.6B
$50.1K 0.93%
+250,500
New +$47.8M
CMPX icon
39
Compass Therapeutics
CMPX
$357M
$50.1K 0.93%
21,960,850
– –
BLU
40
DELISTED
BELLUS Health Inc.
BLU
$49K 0.91%
4,634,900
+3,180,100
+219% +$33.8M
KNTE
41
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$48.3K 0.9%
4,043,629
– –
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.68B
$48.2K 0.9%
2,006,500
-316,800
-14% -$7.11M
SPRY icon
43
ARS Pharmaceuticals
SPRY
$566M
$46.2K 0.86%
8,740,887
– –
TERN
44
DELISTED
Terns Pharmaceuticals
TERN
$44.1K 0.82%
7,481,204
+3,690,000
+97% +$13.7M
ACRS icon
45
Aclaris Therapeutics
ACRS
$723M
$43.4K 0.81%
2,758,434
+432,934
+19% +$6.82M
PGNY icon
46
Progyny
PGNY
$2.46B
$42K 0.78%
1,134,053
+509,053
+81% +$19.1M
ABCL icon
47
AbCellera Biologics
ABCL
$1.64B
$41.3K 0.77%
4,180,768
– –
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.21B
$41.1K 0.76%
1,137,300
-191,900
-14% -$6.9M
RPTX
49
DELISTED
Repare Therapeutics
RPTX
$40.3K 0.75%
3,322,488
– –
KDNY
50
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$39.9K 0.74%
2,029,300
+133,000
+7% +$2.67M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39M, down 2.4% from $5.52M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed deployed $358M of net new capital in Q3 2022, opening 15 new positions and adding to 31 existing holdings. Its largest new stake was Third Harmonic Bio: 5,779,071 shares worth $110K.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $81.3M trimmed.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110K.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168K.
  • OrbiMed's ten largest holdings make up 31% of its $5.39M portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39M.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.